Combination of Reolysin, Opdivo, and Standard of Care to Be Tested in Phase 1 Trial for Multiple Myeloma
A combination of Oncolytics Biotech’s investigational therapy…
Myeloma
Myeloma overview
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
Read moreMyeloma treatment
While myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Read moreLatest news
Once-weekly Kyprolis with Dexamethasone Approved in US for Relapsed or Refractory Multiple Myeloma
The U.S. Food and Drug Administration has approved…
Takeda, Molecular Templates Partner to Develop Next-generation IO for Multiple Myeloma
Molecular Templates has partnered with Takeda to develop engineered toxin…
EMA Begins Review Process for Empliciti Triple Combo for Relapsed or Refractory Multiple Myeloma
The European Medicines Agency has validated Bristol-Myers Squibb’s…
Karyopharm’s Selinexor Demonstrates High Response Rates in Heavily-treated Multiple Myeloma Patients
Updated results from a Phase 2b clinical trial continue…
Patient Power, Winship Cancer Institute Partnered for Myeloma Town Hall Meeting
In an effort to inform multiple myeloma patients…
